VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

CpHV-1 Vaccine MF59 Adjuvant
Vaccine Information
  • Vaccine Name: CpHV-1 Vaccine MF59 Adjuvant
  • Target Pathogen: Caprine herpesvirus type 1 (CpHV-1)
  • Type: Inactivated or "killed" vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Antigen: CpHV-1 (Marinaro et al., 2012)
  • Immunization Route: subcutaneous injection
  • Description: inactivated CpHV-1 plus MF59™ as adjuvant was strongly immunogenic and induced effective immunity against vaginal CpHV-1 infection in goats. (Marinaro et al., 2012)
Host Response

Goat Response

  • Vaccination Protocol: The twenty-eight goats received either 2 ml of inactivated CpHV-1 (10^6.5 TCID50/50 µl) plus 2 ml of sterile saline solution or received 2 ml of inactivated CpHV-1 emulsified with 2 ml of MF59™ or were left unvaccinated (these animals served as naïve controls in challenge studies). After preparation, vaccines were immediately injected subcutaneously in the neck. All goats were vaccinated with two doses of vaccine (one dose on day 0 and one dose on day 10). (Marinaro et al., 2012)
  • Immune Response: Detection and quantitation of latent CpHV-1 DNA in sacral ganglia in challenged goats revealed that the inactivated CpHV-1 plus MF59™ vaccine was able to significantly reduce the latent viral load when compared either to the naïve goats or to the goats vaccinated with inactivated CpHV-1 in the absence of adjuvant. (Marinaro et al., 2012)
  • Side Effects: No systemic adverse reactions were observed in any goat included in the study. (Marinaro et al., 2012)
  • Challenge Protocol: The vaginal challenge was performed by pipetting four milliliters of virulent CpHV-1 suspension (10^5 TCID50/50 µl) into the vaginal lumen of naïve animals or vaccinated animals (Marinaro et al., 2012).
  • Efficacy: Vaginal disease was not detected in goats vaccinated with inactivated CpHV-1 plus MF59™ and these animals had undetectable levels of infectious challenge virus in their vaginal washes. Goats vaccinated with inactivated CpHV-1 in the absence of adjuvant exhibited a less severe disease when compared to naïve goats but shed titers of challenge virus that were similar to those of naïve goats. (Marinaro et al., 2012)
References